Breakthrough in Cancer Immunotherapy: Researchers Develop Nanovaccine to Eradicate Cancer Stem Cells

Cancer scientists at the National University of Singapore have made a groundbreaking discovery in the field of immunotherapy, developing a novel nanovaccine strategy to target and eliminate cancer stem cells, which cause tumour recurrence and incurability after surgery. The researchers, led by Dr. Gege Wu, propose a nanovaccine called NICER, which combines CSC-specific antigen display and epigenetic nano-regulator encapsulation with a dendritic-cell-targeting aptamer to eradicate CSCs and bulk tumour cells simultaneously. This pioneering approach has shown significant promise in inhibiting postoperative cancer recurrence and metastasis, leading to prolonged survival rates.

Key Takeaways:

• The NICER nanovaccine approach is a broad-spectrum vaccine strategy that targets both cancer stem cells and bulk tumour cells, making it an effective solution for postoperative cancer immunotherapy.
• The nanovesicles derived from aldehyde-dehydrogenase-overexpressing tumours can serve as integrated antigens carrying both CSC-specific antigen and tumour-associated antigen.
• The epigenetic nano-regulator targeting YTH N-methyladenosine RNA binding protein 1 can restrict dendritic cell lysosomal protease activity to modulate the effective cross-presentation of integrated antigens via major histocompatibility complex class I for immune responses.
• The NICER nanovaccine has shown significant promise in inhibiting postoperative cancer recurrence and metastasis, prolonging survival rates.
• The research has been peer-reviewed and published in Nature Nanotechnology.
• Additional authors for the research include Qing You, Hui Li, Jingyi Liu, Fangfang Cao, Lingwen Ding, Fuming Liang, Bo Zhou, Lilusi Ma, Ling Zhu, Chen Wang, Yanlian Yang, and Xiaoyuan Chen.
• The researchers propose the NICER nanovaccine approach as an efficient strategy for tracking and eradicating CSCs.

Statistics:

• The NICER nanovaccine approach has shown significant promise in inhibiting postoperative cancer recurrence and metastasis, leading to prolonged survival rates.
• The nanovesicles derived from aldehyde-dehydrogenase-overexpressing tumours can be used as integrated antigens carrying both CSC-specific antigen and tumour-associated antigen.
• The epigenetic nano-regulator targeting YTH N-methyladenosine RNA binding protein 1 has a significant impact on modulating the effective cross-presentation of integrated antigens via major histocompatibility complex class I.
• The NICER nanovaccine approach targets both cancer stem cells and bulk tumour cells, making it a broad-spectrum vaccine strategy.

Sources:

• A nanovaccine targeting cancer stem cells and bulk cancer cells for postoperative cancer immunotherapy. Nature Nanotechnology, 2025.
• National University of Singapore Reports Findings in Vaccines (A nanovaccine targeting cancer stem cells and bulk cancer cells for postoperative cancer immunotherapy). Nanotechnology Weekly. June 30, 2025; p 621.